Objectives. To describe the incidence and prevalence of peripheral neuropathy in ANCA-associated vasculitis (AAV); to evaluate the correlation of neuropathy with other clinical manifestations; and to review the long-term outcome of treated neuropathy.
Introduction
Granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis (MPA) are both necrotizing systemic vasculitides that affect small blood vessels (arterioles, capillaries and venules) and have a strong association with ANCAs [1] . Granulomatous inflammation of the respiratory tract with a cytoplasmic pattern of ANCA staining on IF (cANCA), which has an affinity to proteinase 3 (PR3), is the hallmark of granulomatosis with polyangiitis [2] . In contrast, MPA is not associated with granulomatous inflammation, but is a necrotizing vasculitis with little or no immune deposit [1] . The finding of a peri-nuclear pattern of ANCA staining (pANCA) that is specific to MPO is a feature of MPA [3] . GN and pulmonary capillaritis are well-studied manifestations of both these disease [48] .
Peripheral neuropathy is reported to be a feature in up to 58% of patients with granulomatosis with polyangiitis and MPA [912] and is commonly present at the onset of disease [9, 13] . The aetiology of the neuropathy in this setting is ischaemic occlusion of the vasa nervosum (i.e. occlusion of the small blood vessels that supply the nerves). Large myelinated sensory and motor fibres are typically affected as they are more prone to ischaemic damage. The insult is axonal rather than demyelinating. Patients often experience pain and may have an acute or subacute presentation [10] . Current treatment strategies for vasculitis-associated neuropathy depend largely on extrapolation from trials of treatment for other organ manifestations because few studies have directly addressed the effect of immunosuppression on vasculitic neuropathy itself [14] . Furthermore, there is very limited evidence comparing the incidence and prevalence of neuropathy with other features of systemic vasculitis and the correlation of treatment responses of these other manifestations with improvement in peripheral neuropathy.
The European Vasculitis Study Group (EUVAS) has completed several trials on the treatment of ANCAassociated vasculitis (AAV) [7, 8, 15, 16] . More than 5 years of follow-up data are now available for four of the trials encompassing 535 patients with granulomatosis with polyangiitis or MPA, stratified by degree of renal involvement. Detailed clinical evaluation, including peripheral neuropathy, was systematically captured during the studies. The aim of this study is to describe the incidence and prevalence of neuropathy in newly diagnosed AAV over a follow-up period of 5 years; evaluate the correlation of neuropathy with other clinical features of systemic vasculitis; and review the long-term outcome of peripheral neuropathy in patients with treated ANCA vasculitis.
Patients and methods
The four EUVAS trials of patients with newly diagnosed granulomatosis with polyangiitis or MPA (which included renal-limited vasculitis) with long-term follow-up have previously been described (MEPEX [8] , CYCLOPS [7] , CYCAZAREM [16] and NORAM [15] ). All four trials were designed to have standardized data collection and disease scoring [17] . The trials excluded patients with ChurgStrauss syndrome. Vasculitis disease activity was measured using the BVAS version 2 [18, 19] and damage using the vasculitis damage index (VDI) [20] . Patients were stratified into the four trials by the severity of renal involvement. A summary of the trials including the drug regimens used is provided in Table 1 . Disease activity (BVAS) was measured at 0, 1.5, 3, 6, 9, 12, 15, 18 months and disease damage (VDI) at 0, 6, 12 and 18 months, except in the MEPEX trial, where the study duration was 12 months. Long-term follow-up (5 years) was conducted as a separate study, which consisted of a questionnaire on patient survival, cardiovascular events, skeletal fractures, severe infection and immunosuppressive therapy, as well as completion of the VDI at 5 years from entry into the original trial by the original trial investigators. Relevant ethical approval was obtained by all participating centres.
We determined the presence or absence of symptomatic peripheral neuropathy by looking at the individual BVAS and VDI items scored during the original trials at all available time points and the VDI completed at 5 years in the long-term follow-up study. BVAS is a clinical checklist of items organized into nine categories: general, cutaneous, mucous membranes/eyes, ENT, chest, cardiovascular, abdominal, renal and nervous system. These categories are usually referred to as organ systems [21] . Individual items are only scored on the BVAS if are directly attributed to active vasculitis. Each item on BVAS is recorded based on the investigator making a clinical judgement at the time of assessment and not necessarily correlated with direct laboratory, radiology or electrophysiology evidence. BVAS captures sensory neuropathy and motor mononeuritis multiplex as two separate items within the nervous system category. Sensory neuropathy is defined in BVAS version 2 (the version used in the EUVAS trials) as an objective sensory deficit in a glove or stocking distribution. Therefore, patients who had only tingling, neuropathic pain or radicular symptoms were not considered to have a sensory neuropathy. Mononeuritis multiplex is defined as objective motor weakness in multiple peripheral nerve distributions (i.e. more than one motor nerve had to be affected for this to be scored). In practice, the treating physicians used the sensory neuropathy category to mean pure sensory without weakness and the motor mononeuritis multiplex category to mean any neuropathy with motor weakness with or without sensory loss. A single patient could theoretically have had both sensory neuropathy and motor mononeuritis multiplex scored on BVAS if they met the relevant definitions for each category, but this did not happen. In general, patients were examined for neuropathy only if they were symptomatic. In addition, neuropathy was only scored on BVAS (i.e. given attribution to active vasculitis) once other causes of neuropathy were excluded. Each item on BVAS version 2 has a separate score for new/worse disease and for persistent disease. For the purposes of this analysis, BVAS version 2 results were mapped to the new version of BVAS (version 3). BVAS version 3 retains the majority of individual items, but the box for new/worse and persistent disease is removed for each item and replaced with a single box at the end of the form, which is ticked if all items scored on BVAS are due to persistent disease only. In the older version of BVAS, there is a separate total score for new/ worse disease and for persistent disease, whereas BVAS version 3 only has a single score, which is essentially a composite of two separate scores derived from the earlier version. Any sensory or motor neuropathy scored on BVAS version 3 (which includes new/worse or persistent disease) was considered an active vasculitic neuropathy in the present study.
www.rheumatology.oxfordjournals.org In contrast, VDI is a checklist of items organized into 11 categories (musculoskeletal, skin/mucous membranes, ocular, ENT, pulmonary, cardiovascular, peripheral vascular disease, gastrointestinal, renal, neuropsychiatric and other), which documents damage (irreversible scarring) that has occurred after the onset of vasculitis irrespective of aetiology. By definition, the damage must be present for at least 3 months before it is recorded. In the VDI, symptomatic neuropathy is captured as a single item within the neuropsychiatric category with no discrimination between sensory and motor neuropathies. Once an item is recorded on the VDI, it is carried forward to all future assessments: i.e. once peripheral neuropathy is ticked (which can happen after 3 months of persistent symptoms), it will always be carried forward irrespective of whether or not symptoms and signs resolve at a later time point. The term chronic neuropathy is used in this article to describe neuropathy as recorded on the VDI.
The determination of symptomatic neuropathy was made at the discretion of the trial physician (which may have involved nerve conduction studies or assessment by a neurologist, but this was not mandatory). We described the prevalence of cranial nerve palsy at trial onset, but did not consider cranial nerve palsy to be a peripheral neuropathy for this study. Relapse was defined by the recurrence or first appearance of at least 1 of the 24 items on the BVAS that are indicative of threatened function of a vital organ or by the recurrence or first appearance of at least three other BVAS items. Neuropathy was not considered a vital organ in the definition of relapse.
Statistical analysis
Data were analysed using the following statistical software packages: R version 2.9.1 (R Foundation, Vienna, Austria), Stata version 10.1 (College Station, TX, USA) and PASW version 18.0 (SPSS Inc., Chicago, IL, USA). Univariate and multivariate odds ratios (ORs) were calculated for predictor variables against the outcome of interest. Student's t-tests were used to compare the difference in means for normally distributed variables and MannWhitney U-tests for non-parametric variables. Chi-squared test was used to compare the difference of proportions. A two-tailed P-value of 4 0.05 was considered statistically significant.
Results
Of 535 patients included in the long-term follow-up study, 31 were excluded due to insufficient baseline or follow-up data. The remaining 506 (237 MPA and 269 granulomatosis with polyangiitis) patients were used for this analysis and baseline characteristics are provided in Table 2 At baseline, patients with active vasculitic neuropathy were more likely to have general systemic features (including arthralgia, arthritis, myalgia, fever and weight loss) compared with those without neuropathy; OR adjusted for age and sex was 1.81 (95% CI 1.19, 2.75); P = 0.005. There was a trend for the association with general systemic features to be stronger in patients with granulomatosis with polyangiitis compared with MPA, but this was not statistically significant. Patients with active vasculitic neuropathy were also more likely to have nonlife-threatening manifestations of disease at trial onset such as cutaneous, mucous membrane and ENT involvement. There was no relationship between the presence or absence of neuropathy compared with the occurrence of life-threatening organ involvement (chest, renal, cardiovascular and abdominal.) The full list of BVAS categories and likelihood of involvement in patients with vasculitic neuropathy stratified by diagnosis is listed in Table 3 . There were no statistically significant differences between granulomatosis with polyangiitis and MPA.
Patients with active vasculitic neuropathy at baseline had a median of 5 organ systems involved (range 38) compared with 4 (range 08) for those without neuropathy, mean 4.9 (95% CI 4.5, 5.4) vs 4.1 (95% CI 3.9, 4.2), respectively (P < 0.001). Baseline disease activity in patients with vasculitic neuropathy (combined sensory and/or motor) was higher (mean BVAS v.3 score 29.7) compared with those without peripheral neuropathy (mean BVAS v3. score 19.5) (P < 0.001). The mean time to achieve a BVAS v.3 score of 0 was the same for those with and without neuropathy at baseline (5.9 months). Of the 40 patients with vasculitic neuropathy at baseline (Table 4) , all 40 achieved remission from active neuropathy within 9 months (as recorded in the BVAS), 14 (35%) without long-term damage (i.e. no neuropathy recorded on the VDI). The remaining 26 (65%) patients developed what we termed chronic neuropathy (i.e. damage lasting longer than 3 months as recorded on the VDI) despite remission from active vasculitic neuropathy. Figure 1 shows the time course for resolution of active neuropathy in 40 patients affected at onset. Of the patients with active vasculitic neuropathy at baseline, 10 (25%) out of 40 died within 5 years compared with 80 (18%) out of 450 without neuropathy (P = 0.26). The hazard ratio (HR) for death adjusted for age, sex and renal function for patients with vasculitic neuropathy at baseline was 1.64 (95% CI 0.85, 3.19); P = 0.142.
Chronic neuropathy that developed after disease onset and had lasted for at least 3 months was documented by VDI in 14 (3%) patients at trial entry (indicating these patients had already suffered neuropathy for at least 3 months), 52 (11%) patients by 12 months and 75 (15%) patients by 60 months (Fig. 2) . These figures are probably an overestimate because the VDI does not detect any improvement in neuropathy once it has been present for over 3 months. Figure 3 shows the overall cumulative prevalence of neuropathy as documented by BVAS and VDI. In total, there were 94 (18.6%) patients with neuropathy documented on BVAS or VDI by 5 years. Of the 75 patients with chronic neuropathy by 5 years, only 29 had an active vasculitic process affecting their peripheral nerves during the original study period. The underlying aetiology for the chronic neuropathy in the remaining 46 patients is unknown. The contribution of vasculitis relapse to the incidence of chronic neuropathy was assessed in the 357 patients in whom relapse data were available. Although 22 (48%) out of 46 patients without a definite underlying cause for chronic neuropathy at 5 years had at least one relapse of active vasculitis during this time, this figure was not significantly different from the relapse rate in patients without chronic neuropathy by 5 years [116 (37%) out of 311, P = 0.17]. However, among the 75 patients with chronic neuropathy by 5 years, the mean (S.D.) number of vasculitis relapses per person was 0.93 (1.19) compared with 0.70 (1.12) for those without neuropathy (P = 0.03). On multivariable analysis (adjusting for age, gender, baseline renal function, baseline BVAS and PR3 and MPO ANCA status), patients with chronic neuropathy occurring within 5 years were more likely to be older [HR = 1.03 for every 1-year increase in age (95% CI 1.01, 1.05), P = 0.009], have a higher BVAS at baseline [HR = 1.07 for a 1-point increase in BVAS (95% CI 1.04, 1.11), P < 0.001] and have a lower serum creatinine (HR = 0.82 for every 100-mmol increase in creatinine (95% CI 0.72, 0.93), P = 0.002]. Gender and PR3 and MPO ANCA status were not associated with chronic neuropathy occurring within 5 years. Diabetes at baseline was not included in the analysis because of missing data on 105 (21%) patients.
Discussion
The availability of long-term outcome data on over 500 incident patients with ANCA vasculitis has permitted the investigation into the frequency and outcome of vasculitic neuropathy in ANCA vasculitis patients. Symptomatic vasculitic neuropathy occurred in 8% of patients with granulomatosis with polyangiitis and MPA at the time of first presentation. With aggressive immunosuppressive therapy, all patients with active vasculitic neuropathy at baseline achieved remission from their neuropathy within 9 months (as defined by the BVAS), 35% of whom had no long-term peripheral nervous system sequelae (as defined by the VDI). On the other hand, by 5 years, 15% of patients with granulomatosis with polyangiitis and MPA had accumulated symptomatic chronic peripheral nerve damage. Once the immediate life-threatening aspects of vasculitis have been managed, Based on being scored or not on the BVAS. b Based on no longer having a sensory or motor neuropathy scored on BVAS v.3 and not having a VDI item for neuropathy scored at any later time point. All patients who achieved complete remission of neuropathy did so by 6 months, which was the first time VDI was scored after baseline.
FIG. 1
Proportion of the 40 patients with active vasculitic neuropathy at baseline who continue to have active vasculitic neuropathy documented on the BVAS over time.
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Of the patients who developed chronic neuropathy by 5 years, about one-third had active vasculitic neuropathy during the original study period, representing the likely cause of the chronic damage. However, in the remaining two-thirds of patients, the aetiology is unclear. A proportion of these patients may have developed a vasculitic neuropathy that was sufficiently insidious as to have   FIG. 2 Cumulative damage in the first 5 years of follow-up. Damage is based on an item being scored on the VDI. For chronic neuropathy to be documented by the VDI, it must have developed after the onset of vasculitis and be present for at least 3 months, but may be of any aetiology.
FIG. 3
Prevalence of peripheral neuropathy during the EUVAS trials. For chronic neuropathy to be documented by VDI, it must have developed after the onset of vasculitis and be present for at least 3 months, but may be of any aetiology. The VDI assesses cumulative prevalence: once neuropathy is present, it remains at all future time points. PN: peripheral neuropathy. escaped capture during the original studies or that emerged with disease relapse after the end of the trials, but neuropathy from diabetes, uraemia, vitamin B12 deficiency, medications or other incidental factors are alternative explanations. Interestingly, a lower serum creatinine at baseline was associated with the development of a chronic neuropathy by 5 years. Patients with lower creatinine would have received less aggressive immunosuppressive therapy, which may be a contributing factor, but alternatively, patients with high serum creatinine are more likely to die early and, therefore, peripheral neuropathy may not have been recognized in this group of patients.
In comparison with the 18.6% of patients with documented neuropathy at any time point in our cohort, a retrospective review of 85 patients with MPA enrolled in various clinical trials by the French Vasculitis Study Group (FVSG) showed that 58% of patients had neuropathy during an average of 70 months of followup [12] , while 44% of 128 granulomatosis with polyangiitis patients in a prospective German cohort developed neuropathy during mean follow-up of 19 months [9] . The FVSG figure included patients with cranial neuropathy (7%), but after excluding these patients, the proportion of patients with neuropathy was still much higher than in the EUVAS cohort. All patients in the German cohort underwent regular assessment by a consultant neurologist and nerve conduction testing, which may explain the larger proportion of patients with documented neuropathy in this study [9] . In contrast, only 0.5% of patients in the Wegener's Granulomatosis Etanercept Trial (WGET) were identified as developing chronic peripheral neuropathy from a vasculitic cause (medium follow-up of 25 months) [24] . The WGET trial used a similar method of identifying neuropathy to that employed in this study. Therefore, there were probably a large number of patients in the EUVAS and WGET cohorts with asymptomatic peripheral neuropathy.
There are limitations to this study. The data analysed here are retrospective extrapolation from four studies with long-term follow-up whose primary endpoints were focused on renal function, overall disease activity, death and cardiovascular outcomes, not peripheral neuropathy. The study investigators were mainly nephrologists and rheumatologists who may not have assessed peripheral neuropathy accurately. We do not know how many of the patients had electrophysiological confirmation of neuropathy or how many patients with neuropathy were missed because the study investigators did not ask the right question or do a thorough neurological examination. The VDI definition of chronic neuropathy includes all patients in whom there was clinical evidence of neuropathy lasting at least 3 months, which means that some of the patients included in this group probably had partial or complete recovery of their neuropathy. The BVAS and VDI were not designed by neuropathy experts and are a crude way of assessing neuropathy. Both are clinical checklists, and individual items may not have been investigated or scored if patients did not complain of neuropathic symptoms. For these reasons, it is very likely that the overall prevalence of active vasculitic neuropathy was underestimated in this study, whereas the prevalence of chronic neuropathic symptoms at 5 years may be an overestimate because recovery of chronic neuropathy lasting over 3 months was not been assessed. The distribution of nerves affected, presence or absence of neuropathic pain and neuropathy severity were not recorded. Moreover, the number of patients with neuropathy in each trial was small, making it difficult to identify specific trends between the different treatment strategies and neuropathy outcomes.
In summary, during the first 5 years after diagnosis of granulomatosis with polyangiitis and MPA, 15% of patients developed chronic peripheral neuropathy lasting over 3 months. It is unclear how many of these chronic neuropathies were caused by vasculitic nerve injury directly as opposed to other factors such as uraemia, drug toxicity and diabetes. With the strong move towards patient-reported outcomes and damage as the benchmark for assessing success of treatment [25] , recognizing complications such as peripheral neuropathy and devising appropriate preventative and treatment strategies is increasingly important when managing patients with systemic vasculitis.
Rheumatology key messages
. Symptomatic peripheral neuropathy is an occasional feature of AAV. . Neuropathy is not associated with life-threatening manifestations of vasculitis. . Vasculitic neuropathy usually affects motor nerves and is long lasting.
